President and COO
Dr. Wu Xiaobin is a pharmaceutical industry executive and corporate insider who serves as President and Chief Operating Officer (COO) of BeOne Medicines Ltd. (ONC).[[2]](https://www.investing.com/news/insider-trading-news/wu-xiaobin-president-and-coo-of-beone-sells-152m-in-stock-93CH-4368967)[[6]](https://www.stocktitan.net/sec-filings/ONC/form-4-be-one-medicines-ltd-insider-trading-activity-25a99a3596c9.html)[[8]](https://beonemedicines.com/about/leadership/) In this role, he oversees global operations and execution for BeOne, a Switzerland‑domiciled oncology company headquartered in Cambridge, United States, that focuses on developing innovative, more affordable cancer therapies across hematologic malignancies and solid tumors.[[1]](https://theorg.com/org/beone-medicines/org-chart/xiaobin-wu)[[8]](https://beonemedicines.com/about/leadership/) As a reporting insider, Wu has disclosed multiple trades in BeOne’s American Depositary Shares (ADS), including sales executed in November 2025 and a tax‑withholding‑related sale of 1,484 ADS on June 8, 2026, while retaining a substantial ongoing equity stake in the company.[[2]](https://www.investing.com/news/insider-trading-news/wu-xiaobin-president-and-coo-of-beone-sells-152m-in-stock-93CH-4368967)[[6]](https://www.stocktitan.net/sec-filings/ONC/form-4-be-one-medicines-ltd-insider-trading-activity-25a99a3596c9.html)
Wu brings more than 25 years of experience in the pharmaceutical industry, including extensive leadership of China operations for major multinational companies.[[1]](https://theorg.com/org/beone-medicines/org-chart/xiaobin-wu)[[5]](https://cbiic.phirda.com/portal/index/speakerdetail/id/736/category_id/25.html?lang=en-us) Before joining BeOne, he served as Global President and Chief Operating Officer at BeiGene and previously held senior roles such as Regional President for Pfizer Essential Health in Greater China, President and Managing Director for Wyeth China and Hong Kong, and General Manager for Bayer Healthcare in China, building expertise across R&D integration, strategy, commercialization, and general management.[[1]](https://theorg.com/org/beone-medicines/org-chart/xiaobin-wu)[[3]](https://www.pharmexec.com/view/leading-man-s-next-act)[[5]](https://cbiic.phirda.com/portal/index/speakerdetail/id/736/category_id/25.html?lang=en-us) He holds a Ph.D. in Biochemistry and Pharmacology and a master’s degree in Molecular Biology from the University of Konstanz in Germany, credentials that underpin his leadership at the intersection of science and global oncology business development.[[1]](https://theorg.com/org/beone-medicines/org-chart/xiaobin-wu)[[5]](https://cbiic.phirda.com/portal/index/speakerdetail/id/736/category_id/25.html?lang=en-us)
View full insider profile →
Discussion